title: [Side effects during dobutamine stress echocardiography: analysis of 582 studies].
abstract: The purpose of the study was to assess the safety, adverse effects and complications of the dobutamine stress echocardiography (ED). 582 patients without previous infarction were prospectively studied with ED. There were 196 female and 368 male, age varied from 27 to 74 years, mean 52. Dobutamine was given in stepwise increasing doses from 5 to 40 mcg/kg/min. Mean maximal dose achieved was 33 mcg/kg/min. Atropine was added in 253 (43%) cases. Significant coronary artery disease was present in 323 patients (53%). There were no death, no myocardial infarction or episodes of sustained ventricular tachycardia as a result of ED. The test was terminated when following conditions were revealed: target heart rate (28.9%), maximal established dose achieved (25.3%), left ventricular asynergy (19.6%), angina pectoris (10.8%), increase of systolic blood pressure above 220 mm Hg (2.6%), hypotension (7.6%), nonsustained ventricular tachycardia (1.7%). The most common non-cardiac side effects were skin tingling (19.8%), atypical chest pain(16.3%), palpitations (13.9%) and headache (7.9%). The most side effects were usually well tolerated, without the need for test cessation. The ED was terminated only in 4 (0.6%) patients because of non-cardiac side effects including nausea (0.3%) and headache (0.3%). We conclude that ED may be safely performed in routine clinical practice. Side effects were rare and usually minor. Most severe ischemic pain was relieved by test interruption and sublingual nitro-glycerine or short acting beta-blocker administration.
authors.affiliation: Kliniki Kardiologii Pomorskiej, Akademii Medycznej w Szczecinie.
authors.forename: E
authors.initials: E
authors.lastname: Płońska
authors.forename: H
authors.initials: H
authors.lastname: Szwed
authors.forename: Z
authors.initials: Z
authors.lastname: Gasior
authors.forename: J
authors.initials: J
authors.lastname: Drozdz
authors.forename: A
authors.initials: A
authors.lastname: Gackowski
authors.forename: A
authors.initials: A
authors.lastname: Szyszka
authors.forename: A
authors.initials: A
authors.lastname: Sieńko
authors.forename: J
authors.initials: J
authors.lastname: Flasiński
authors.forename: I
authors.initials: I
authors.lastname: Swiatkiewicz
authors.forename: M
authors.initials: M
authors.lastname: Sas
authors.forename: M
authors.initials: M
authors.lastname: Demczuk
authors.forename: A
authors.initials: A
authors.lastname: Kleinrok
authors.forename: E
authors.initials: E
authors.lastname: Krzymińska
mesh_terms: D000328:Adult; D000368:Aged; D001285:Atropine; D002316:Cardiotonic Agents / Q000009:adverse effects*; D003327:Coronary Disease / Q000175:diagnosis; D004280:Dobutamine / Q000009:adverse effects*; D004562:Electrocardiography / Q000187:drug effects*; D005080:Exercise Test / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics; D011446:Prospective Studies
chemical_list: D002316:Cardiotonic Agents; D010276:Parasympatholytics; D004280:Dobutamine; D001285:Atropine